Items with tag "crohn's disease"

News

New drug for intestinal fibrosis

Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especially in patients with Crohn's disease. Today, intes…

Read more

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

Galapagos NV announced two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being led by filgotinib collabor…

Read more

Cell therapy for Crohn's disease gets FDA boost to enter US market

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has r…

Read more

Tigenix' cash position gets stronger and stronger

Tigenix received in July a contribution of 25 million euros from Takeda, which doubled its cash position. The Japanese company wants to market Cx601, Tigenix' flagship product. Cx601 is a trea…

Read more

TiGenix inks massive deal with Takeda

Today cell therapy specialist TiGenix has disclosed a new deal with the Japanese pharmaceutical giant Takeda. The agreement allows Takeda the rights to license, develop and sell TiGenix’ Cx601 glo…

Read more

Major breakthrough in Tigenix' Crohn's research

About one year ago, patients received a single injection of Cx601. Half of the patients were healed after 24 weeks. One year later, 1 in 2 (54%) patients still experiences the positive effect of t…

Read more

Galapagos finally managed to close long awaited deal

Earlier this year, AbbVie turned down its deal with Galapagos for co-development and commercializiation of the drug filgotinib for treatment of reumathoid arthritis. Last week, Galapagos announced…

Read more

Galapagos' drug also active against Crohn's disease!

Galapagos has been working for a while on a drug, called Filgotinib, against rheumatoid arthritis. But this drug candidate also appears to have other therapeutic properties. Galapagos is now evalu…

Read more

Insights

AbbVie: a biotech company in a pharma coat

AbbVie: a biotech company in a pharma coat

AbbVie was created as a spin-out of the pharmaceutical activities from industry giant Abbott Laboratories just over 3 years ago. This has proven to be a smart decision—despite fluctuating markets,…

Read more

Faeces transplant as treatment for Crohn's disease

Faeces transplant as treatment for Crohn's disease

Crohn’s disease is a complicated chronic disorder, the complexity of which has only become clear during the last decade. It has become increasingly evident that your food pattern and gut microbiot…

Read more

Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related disease, causing abdominal pain, diarrhea, fever a…

Read more

The success of adipose stem cells

The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoint of their European phase three clinical trial. T…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent GSK KU Leuven Biowin XpandInnovation V-Bio Ventures Flanders.bio Janssen Turnstone Itera Life Science

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.